Exploring a New Treatment for Metastatic Colorectal Cancer
The Rutgers Cancer Institute is conducting a phase II clinical trial to evaluate whether a combined vaccine (CV301) and the immunotherapy drug nivolumab can improve outcomes for patients with metastatic colorectal cancer that has spread to the liver.
This article discusses a phase II clinical trial at Rutgers Cancer Institute of New Jersey that tests a novel combination therapy for metastatic colorectal cancer involving the CV301 vaccine and the checkpoint inhibitor nivolumab, aimed at preventing recurrence after liver-directed surgery and standard chemotherapy. The trial seeks to compare the efficacy of this combination versus nivolumab plus chemotherapy and surgery alone.
Metastatic colorectal cancer has a high rate of recurrence after standard surgery and chemotherapy, leading to poor survival. Introducing a vaccine-based immunotherapy to enhance the immune response could reduce relapse rates and improve long‑term outcomes for patients with liver‑metastasized disease.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics